Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The purpose of this study was to compare the effectiveness and tolerability of tranylcypromine and combination treatment with extended-release venlafaxine and mirtazapine in patients with treatment-resistant major depression whose current depressive episode had not responded adequately to treatment in three prior prospective medication trials. METHOD: Adult outpatients with nonpsychotic major depressive disorder who had not achieved remission or had withdrawn from treatment because of intolerance in three previous prospective medication trials were randomly assigned to receive open-label treatment with either tranylcypromine (N=58) or extended-release venlafaxine plus mirtazapine (N=51). The primary outcome measure was whether patients achieved remission, which was defined as a score < or =7 at exit on the 17-item Hamilton Depression Rating Scale (HAM-D). The HAM-D was administered by telephone by raters to whom treatment was masked. RESULTS: Remission rates were not significantly different between the two treatment groups (6.9% for the tranylcypromine group and 13.7% for the venlafaxine plus mirtazapine group). The mean daily dose at exit for tranylcypromine was 36.9 mg (SD=18.5); for venlafaxine, 210.3 mg (SD=95.2); and for mirtazapine, 35.7 mg (SD=17.6). Tranylcypromine was associated with significantly less symptom reduction and greater attrition due to intolerance. CONCLUSIONS: Remission rates were modest for both the tranylcypromine group and the extended-release venlafaxine plus mirtazapine group, and the rates were not statistically different between groups. The lower side effect burden, lack of dietary restrictions, and ease of use of venlafaxine and mirtazapine suggest that this combination may be preferred over tranylcypromine for patients with highly treatment-resistant depression who have not benefited adequately from several prior treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
WARE, J. E., KOSINSKI, M., & KELLER, S. D. (1996) · Medical Care · doi:10.1097/00005650-199603000-00003 · Cited by 17,392
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Self-citationRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829 · cited 20×
“However, participants could leave a trial early if intolerable side effects occurred, if a remission was sustained for at least 2 weeks, or if minimal symptom reduction (QIDS-C total score >9) had occurred after 6 weeks at maximally tolerated doses.”
MethodInfluentialSelf-citationThe Work and Social Adjustment Scale: a simple measure of impairment in functioning
Mundt, J. C., Marks, I. M., Shear, M. K., & Greist, J. M. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.461 · Cited by 2,515
CUMULATIVE ILLNESS RATING SCALE
LINN, B. S., LINN, M. W., & GUREL, L. (1968) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1968.tb02103.x · Cited by 2,304
Evidence-based health policy—lessons from the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (1996) · Science · doi:10.1126/science.274.5288.740 · Cited by 2,178
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177 · cited 2×
“The presence of atypical (28) and melancholic features (29) was determined with the 30-item Inventory of Depressive Symptomatology—Clinician-Rated (30) in a telephone interview conducted by a research outcomes assessor, and anxious features were assessed by the anxiety subscale of the HAM-D (31).”
MethodSelf-citationMiller, M. D., Paradis, C. F., Houck, P. R., Mazumdar, S., Stack, J. A., Rifai, A. H., Mulsant, B., & Reynolds, C. F. (1992) · Psychiatry Research · doi:10.1016/0165-1781(92)90005-n · Cited by 1,990
Cited by
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Self-citationRaison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617
George, M. S., Lisanby, S. H., Avery, D., McDonald, W. M., Durkalski, V., Pavlicova, M., Anderson, B., Nahas, Z., Bulow, P., Zarkowski, P., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.46 · Cited by 1,092
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
The STAR*D project results: A comprehensive review of findings
Warden, D., Rush, A. J., Trivedi, M. H., Fava, M., & Wisniewski, S. R. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0061-3 · Cited by 727
Self-citationKetamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300059 · Cited by 580
Kennedy, S. H., Lam, R. W., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 525
Preskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518
Connolly, K. R., & Thase, M. E. (2011) · Drugs · doi:10.2165/11587620-000000000-00000 · Cited by 462
Self-citationManagement of Treatment-Resistant Depression: Challenges and Strategies
Voineskos, D., Daskalakis, Z. J., & Blumberger, D. M. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s198774 · Cited by 446
“94 Psychotherapy Psychotherapeutic approaches may be undertaken in combination with somatic or pharmacological treatments, or on their own once several other interventions have been attempted.”
Lam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431
“In the STAR*D effectiveness trial, after nonremission to 3 treatment steps, the combination of mirtazapine with venlafaxine had similar outcomes (although Type II error may have obscured some possible superior outcomes) to tranylcyprominemonotherapy, but the combinationwas better tolerated (McGrath et al., 2006).”
BackgroundThe Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial: A Review
Sinyor, M., Schaffer, A., & Levitt, A. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005500303 · Cited by 396
Rush, A. J., Trivedi, M. H., Stewart, J. W., Nierenberg, A. A., Fava, M., Kurian, B. T., Warden, D., Morris, D. W., Luther, J. F., Husain, M. M., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111645 · Cited by 372
Self-citationJoshi, S. H., Espinoza, R. T., Pirnia, T., Shi, J., Wang, Y., Ayers, B., Leaver, A., Woods, R. P., & Narr, K. L. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.02.029 · Cited by 320
Price, R. B., Shungu, D. C., Mao, X., Nestadt, P., Kelly, C., Collins, K. A., Murrough, J. W., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.10.025 · Cited by 270
Kantrowitz, J., Citrome, L., & Javitt, D. (2009) · CNS Drugs · doi:10.2165/00023210-200923080-00001 · Cited by 260
Consensus statement: The evaluation and treatment of people with epilepsy and affective disorders
Barry, J. J., Ettinger, A. B., Friel, P., Gilliam, F. G., Harden, C. L., Hermann, B., Kanner, A. M., Caplan, R., Plioplys, S., Salpekar, J., et al. (2008) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2008.04.005 · Cited by 249
Ruhé, H. G., Huyser, J., Swinkels, J. A., & Schene, A. H. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1203 · Cited by 230
Gadad, B. S., Jha, M. K., Czysz, A., Furman, J. L., Mayes, T. L., Emslie, M. P., & Trivedi, M. H. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.07.001 · Cited by 205
Self-citationMirtazapine: A Review of its Use in Major Depression and Other Psychiatric Disorders
Croom, K. F., Perry, C. M., & Plosker, G. L. (2009) · CNS Drugs · doi:10.2165/00023210-200923050-00006 · Cited by 158
Avery, D. H., Isenberg, K. E., Sampson, S. M., Janicak, P. G., Lisanby, S. H., Maixner, D. F., Loo, C., Thase, M. E., Demitrack, M. A., & George, M. S. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0315 · Cited by 129
“4%.(16,20) As in the shamcontrolled study, there was an absence of systemic side effects such as weight gain or sexual dysfunction.”
BackgroundSelf-citationCarvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
Blumberger, D. M., Mulsant, B. H., Fitzgerald, P. B., Rajji, T. K., Ravindran, A. V., Young, L. T., Levinson, A. J., & Daskalakis, Z. J. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.579163 · Cited by 118
Sequenced Treatment Alternatives to Relieve Depression (STAR*D): Part 2: Study Outcomes
Howland, R. H. (2008) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20081001-05 · Cited by 115
Giacobbe, P., Mayberg, H. S., & Lozano, A. M. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.04.028 · Cited by 112
Standardisation framework for the Maudsley staging method for treatment resistance in depression
Fekadu, A., Donocik, J. G., & Cleare, A. J. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1679-x · Cited by 106
Pigott, H. E. (2015) · The Canadian Journal of Psychiatry · doi:10.1177/070674371506000104 · Cited by 93
Pigott, H. E., Kim, T., Xu, C., Kirsch, I., & Amsterdam, J. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-063095 · Cited by 93
“Objective Reanalyse the patient-level data set of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study with fidelity to the original research protocol and related publications.”
MethodFriedman, E. S., Davis, L. L., Zisook, S., Wisniewski, S. R., Trivedi, M. H., Fava, M., & Rush, A. J. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.010 · Cited by 81
“Dosing schedules were based on prior reports (Fava, 2001; Papakostas et al., 2005; McGrath et al., 2006; Leuchter et al., 2008).”
MethodSelf-citationA critical review of pharmacotherapy for major depressive disorder.
Dupuy, J. M., Ostacher, M. J., Huffman, J., Perlis, R. H., & Nierenberg, A. A. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000083 · Cited by 61
Self-citationReview of the use of mirtazapine in the treatment of depression
Benjamin, S., & Doraiswamy, P. M. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.585459 · Cited by 46
Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics
de Sousa, R. T., V. Zanetti, M., R. Brunoni, A., & Machado-Vieira, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630173522 · Cited by 43
“The STAR*D study evaluated 109 patients who received venlafaxine plus mirtazapine or tranylcypromine after 3 consecutive trial failures [23].”
MethodCastells, X., Cunill, R., & Capellà, D. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1390-7 · Cited by 41
Amsterdam, J. D., Williams, D., Michelson, D., Adler, L. A., Dunner, D. L., Nierenberg, A. A., Reimherr, F. W., & Schatzberg, A. F. (2009) · Neuropsychobiology · doi:10.1159/000226611 · Cited by 39
Self-citationRational site-directed pharmacotherapy for major depressive disorder
Blier, P. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000400 · Cited by 29
Chan, H. N., Rush, A. J., Nierenberg, A. A., Trivedi, M., Wisniewski, S. R., Balasubramani, G. K., Friedman, E. S., Gaynes, B. N., Davis, L., Morris, D., et al. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001660 · Cited by 30
Self-citation
Metadata
- Authors
- McGrath, P. J., Stewart, J. W., Fava, M., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Thase, M. E., Davis, L., Biggs, M. M., Shores-Wilson, K., Luther, J. F., Niederehe, G., Warden, D., Rush, A. J., & STAR*D Study Team
- Venue
- American Journal of Psychiatry
- Published
- 2006-09
- Volume
- 163
- Issue
- 9
- Pages
- 1531-1541
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2143247032
- Cited by
- 350
- References
- 39
- FWCI
- 20.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.